6.32  0.09 (1.44%)		12-08 12:08
Open: 6.275 High: 6.37 Volume: 198,536		Pre. Close: 6.23 Low: 6.095 Market Cap: 112(M)

Short term
Mid term
Targets	6-month :	7.82	1-year :	9.14
Resists	First :	6.69	Second :	7.82
Pivot price	5.93
Supports	First :	5.2	Second :	4.28
MAs	MA(5) :	6.21	MA(20) :	5.72
	MA(100) :	4.67	MA(250) :	0
MACD	MACD :	0.3	Signal :	0.3
%K %D	K(14,3) :	77.5	D(3) :	76
RSI	RSI(14): 61.9
52-week	High :	11	Low :	3.71

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ UNCY ] has closed below upper band by 25.7%. Bollinger Bands are 50.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	6.61 - 6.64	6.64 - 6.68
Low:	6.12 - 6.16	6.16 - 6.19
Close:	6.17 - 6.24	6.24 - 6.29

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Thu, 04 Dec 2025
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - Louisiana First News

Tue, 18 Nov 2025
Retail investors who hold 48% of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 23%, institutions profited as well - Yahoo Finance

Mon, 17 Nov 2025
Unicycive Therapeutics (NASDAQ:UNCY) Is In A Good Position To Deliver On Growth Plans - simplywall.st

Fri, 14 Nov 2025
Unicycive Therapeutics Doubles Stock Sale Agreement - TipRanks

Wed, 12 Nov 2025
Unicycive (NASDAQ: UNCY) reports 7x lower pill volume, 2x fewer pills with OLC - Stock Titan

Wed, 12 Nov 2025
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	21 (M)
Shares Float	18 (M)
Held by Insiders	2.9 (%)
Held by Institutions	30.3 (%)
Shares Short	1,250 (K)
Shares Short P.Month	1,010 (K)

EPS	-3.45
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.79
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-44.3 %
Return on Equity (ttm)	-102.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.47
Qtrly Earnings Growth	0 %
Operating Cash Flow	-30 (M)
Levered Free Cash Flow	-16 (M)

PE Ratio	-1.84
PEG Ratio	0
Price to Book value	3.49
Price to Sales	0
Price to Cash Flow	-4.54

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.